Skip to main content

Drug maker QLT Inc. posted a net loss of $19.2-million (U.S.) in the fourth quarter compared with a profit of $80,582 in the same prior-year period when it recorded a big gain from discontinued operations.

That is equal to a loss of 38 cents per share in the fourth quarter, compared to earnings of $1.49 per share in the fourth quarter of 2009.

Back in 2009, the company, which reports in U.S. dollars, recorded $116.7-million in gains from the sale of QLT USA.

Story continues below advertisement

In its most recent quarter, revenue was $10-million, down from $10.8-million the year before, while sales of QLT's macular degeneration treatment, Visudyne, declined 19 per cent in the U.S. compared with the fourth quarter in 2009.

QLT also spent $8.1-million more on research and development than in the year-earlier quarter.

Report an error
As of December 20, 2017, we have temporarily removed commenting from our articles. We hope to have this resolved by the end of January 2018. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.